Owkinews: What happened in January?
Owkin announces Owkin K1.0 Turbigo
Bringing together eight years of advanced technologies built by Owkin’s researchers and AI scientists, Owkin K1.0 is a groundbreaking operating system for discovering new disease biology, paving the way for Artificial General Intelligence (AGI) in the field.
Absci and Owkin synergize TechBio platforms to advance Gen AI drug discovery
The collaboration combines Owkin's agentic AI target discovery capabilities with Absci 's de novo design models to accelerate the path to breakthrough therapeutics through our state-of-the-art operating system, Owkin K1.0.
Owkin and Sanofi publish collaborative deep learning research in iScience
Our models accurately predict YAP1/TEAD activity, validated across seven independent cohorts. We identified strong links between dysfunctional Hippo signaling and key tumor characteristics, including necrosis, immune infiltration, and poorly differentiated cells.
This approach provides a reproducible, cost-effective alternative to RNA-seq for detecting dysregulated Hippo signaling, seamlessly integrating AI into clinical workflows.
Read the full study on iScience: https://www.cell.com/iscience/fulltext/S2589-0042(24)02865-7
Bioptimus hits $76M funding milestone
Congratulations to Bioptimus on reaching a $76M funding milestone in less than 12 months since its seed round!
Following the July 2024 launch of the largest AI foundation model for pathology, Bioptimus is now preparing to release a groundbreaking multi-scale, multi-modal biology model in 2025.